Navigation Links
Lung and bladder cancers have common cell-cycle biomarkers

A University of Colorado Cancer Center study published in the journal PLoS ONE shows that bladder and lung cancers are marked by shared differences in the genetics that control the cell cycle. Measuring these genetic signatures could allow doctors to refine a patient's prognosis, choose appropriate treatments, and perhaps offer new treatments that target these shared genetic abnormalities.

"It's exciting: the CU Cancer Center has internationally recognized expertise in these two cancers lung and bladder and with this study we were able to find what is effectively a common denominator between these two major tobacco-related cancers. We know that many cancers rush through the cell cycle to replicate themselves faster than does healthy tissue, and now we see that some of the same processes are at work in both bladder and lung cancers," says Dan Theodorescu, MD, PhD, director of the CU Cancer Center and lead author of the study.

Biomarkers are the differences between cancerous and healthy cells that allow researchers and doctors to diagnose, predict the course of, and increasingly treat cancers. But with about 40,000 genes in the human genome and far more steps between a gene and its expression as a protein, finding meaningful biomarkers is the proverbial search for a needle in a haystack. Traditionally, tissue samples from one cancer type are collected and then the genes in these samples are analyzed to see which, if any, are elevated, silenced or mutated. Unfortunately, despite the success of this approach in identifying candidate biomarkers, many biomarkers fail to stand up to further scrutiny a gene that is elevated in a subset of 10 samples of, say, prostate cancer, may not be elevated in further cohorts of the same cancer.

The current study reasoned that biomarkers present in not just one but two or more related but different cancers would likely be more robust than single-cancer biomarkers. Previous studies link lung and bladder with tobacco use they have a common etiology. And so Theodorescu and postdoctoral fellow Garret Dancik, PhD, gathered hundreds of samples of these cancers to explore them for common causes (or at least common predictive markers). The question was this: with so many tumor samples matched with corresponding patient outcomes, could the researchers pinpoint what it was in these tumors that led to favorable or less good patient results?

First, the researchers correlated gene expression to progression and survival in these samples, ending with a master list of all genes predictive of patient outcomes. Then they crossed these lists to look for commonalities between the cancers. Rather than single genes that predict outcomes in these cancer types, researchers found clusters or "modules" of adjusted genes, all under the umbrella of the network that controls the cell cycle.

"This is important not just because we identified a signature that may be prognostic in bladder and lung cancers, but because the idea of considering a 'module' of genes related to a specific process in this case, the cell cycle may be useful in other cancers, " Theodorescu says.

Contact: Garth Sundem
University of Colorado Denver

Related medicine news :

1. Classification system for bladder cancer prognosis
2. Study could lead to liquid biopsy tests for bladder cancer
3. Actos Lawsuit News: Nation’s Third Actos Trial Involving Bladder Cancer Allegations Now Underway in Nevada State Court, Bernstein Liebhard LLP Reports
4. Actos Bladder Cancer Allegations Attorney Help: Resource4thePeople Comments on Progress of Federal Litigation Involving Cancer Claims Filed against Takeda Pharmaceuticals
5. Yael Fuchs, MD, FACOG, of Gramercy Gynecological Health, PLLC, Receives InTone® Specialist Certification To Help Women Stop Bladder Leakage
6. Actos Bladder Cancer Allegation Lawyer: Resource4thePeople Reports New Cases Involving Cancer Claims Filed against Takeda Pharmaceuticals
7. Millions Suffering from Silent Bladder Health Epidemic Get Chance to Speak Out
8. Harriette M. Scarpero, M.D., & Kate Meriwether, NP, of Associated Urologists of Nashville, LLP, Receive InTone Specialist Certification to Help Women Stop Bladder Leakage
9. Actos Bladder Cancer Lawsuit: Bernstein Liebhard LLP Comments on Outcome of Nation’s Second Actos Lawsuit Trial
10. Actos Lawsuit News: Bernstein Liebhard LLP Comments on Start of Jury Deliberations in Actos Bladder Cancer Trial
11. Actos Lawsuits Move Forward, as Bernstein Liebhard LLP Notes Scheduling of Future Status Conferences in Federal Actos Bladder Cancer Litigation
Post Your Comments:
Related Image:
Lung and bladder cancers have common cell-cycle biomarkers
(Date:10/13/2015)... ... 13, 2015 , ... According to an article published October 5th ... who successfully lose weight with a bariatric procedure are much less likely to develop ... notes that anywhere from 40 to 50 percent of all endometrial cancer cases are ...
(Date:10/13/2015)... , ... October 13, 2015 , ... Symposium Chairman, Dr. ... 19th annual Dallas Cosmetic Symposium to be held March 2nd and 3rd, 2016. The ... afterwards, draws plastic surgeons and cosmetic physicians from around the world. , Key topics ...
(Date:10/13/2015)... ... October 13, 2015 , ... ... unique private messaging application, announced today a significant contract that will provide its ... Independence plans to build on the growing success of its Relay program, IBX ...
(Date:10/13/2015)... ... ... NavaFit Inc. today announced the launch of its NavaFit app for iPhone® ... fitness & sporting events, and stay motivated. Users can download the apps ... to get more serious about fitness and wellness, individuals are constantly looking for new ...
(Date:10/13/2015)... ... 2015 , ... Protein is essential to good health. You need it to ... how much protein does the average man need in order to stay healthy? ... 2015 issue of Harvard Men's Health Watch . Most Americans get about 15% ...
Breaking Medicine News(10 mins):
(Date:10/13/2015)... Calif. , Oct. 13, 2015  Asterias ... agreement with the UK-based Cell Therapy Catapult to ... AST-VAC2, Asterias, allogeneic dendritic cell immunotherapy. Under the ... scale manufacturing processes for AST-VAC2 to support advanced ... --> --> The ...
(Date:10/12/2015)... Apheresis is an invasive process that involves the ... components from whole blood. In this procedure, the blood of ... machine or a blood cell separator. The apheresis equipment spins ... components. A selected part of the blood is removed, and ... patient. It involves the use of devices and disposables along ...
(Date:10/12/2015)... 12, 2015  The Pharmacy Compounding Accreditation Board ... Pharmacy in Costa Mesa , ... the pharmacy,s commitment to meeting and/or exceeding national ... --> --> ... --> --> Harbor Compounding ...
Breaking Medicine Technology: